Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7745609 Antisense modulation of CD40 expression

Patent 7745609 was granted and assigned to Ionis Pharmaceuticals on June, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

Ionis Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Andrew M. Siwkowski0

C. Frank Bennett0

Lex M. Cowsert0

Date of Patent

June 29, 2010

0

Patent Application Number

114663690

Date Filed

August 22, 2006

0

Patent Citations Received

US Patent 12123015 Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

0

US Patent 11674159 Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

0

US Patent 11697814 Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene

0

US Patent 11970711 Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

0

Patent Primary Examiner

Tracy Vivlemore

0

Patent abstract

Antisense compounds, compositions and methods are provided for modulating the expression of CD40. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40. Methods of using these compounds for modulation of CD40 expression and for treatment of diseases associated with CD40 are provided.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7745609 Antisense modulation of CD40 expression

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool